Authors:
Lewin, SR
Ribeiro, RM
Walters, T
Lau, GK
Bowden, S
Locarnini, S
Perelson, AS
Citation: Sr. Lewin et al., Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed, HEPATOLOGY, 34(5), 2001, pp. 1012-1020
Citation: A. Bartholomeusz et S. Locarnini, Hepatitis B virus mutants and fulminant hepatitis B: Fitness plus phenotype, HEPATOLOGY, 34(2), 2001, pp. 432-435
Authors:
Chin, R
Shaw, T
Torresi, J
Sozzi, V
Trautwein, C
Bock, T
Manns, M
Isom, H
Furman, P
Locarnini, S
Citation: R. Chin et al., In vitro susceptibilities of wild-type or drug-resistant hepatitis B virusto (-)-beta-D-2,6-diaminopurine dioxolane and 2 '-fluoro-5-methyl-beta-L-arabinofuranosyluracil, ANTIM AG CH, 45(9), 2001, pp. 2495-2501
Authors:
Delaney, WE
Edwards, R
Colledge, D
Shaw, T
Torresi, J
Miller, TG
Isom, HC
Bock, CT
Manns, MP
Trautwein, C
Locarnini, S
Citation: We. Delaney et al., Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus, ANTIM AG CH, 45(6), 2001, pp. 1705-1713
Authors:
Colonno, RJ
Genovesi, EV
Medina, I
Lamb, L
Durham, SK
Huang, ML
Corey, L
Littlejohn, M
Locarnini, S
Tennant, BC
Rose, B
Clark, JM
Citation: Rj. Colonno et al., Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection, J INFEC DIS, 184(10), 2001, pp. 1236-1245
Authors:
Basuni, AA
Butterworth, LA
Cooksley, G
Locarnini, S
Carman, WF
Citation: Aa. Basuni et al., An efficient extraction method from blood clots for studies requiring bothhost and viral DNA, J VIRAL HEP, 7(3), 2000, pp. 241-243
Authors:
Nicoll, A
Locarnini, S
Chou, ST
Smallwood, R
Angus, P
Citation: A. Nicoll et al., Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo, J GASTR HEP, 15(3), 2000, pp. 304-310
Authors:
Wilson, N
Ruff, TA
Rana, BJ
Leydon, J
Locarnini, S
Citation: N. Wilson et al., The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu, VACCINE, 18(26), 2000, pp. 3059-3066
Authors:
Colledge, D
Civitico, G
Locarnini, S
Shaw, T
Citation: D. Colledge et al., In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir, ANTIM AG CH, 44(3), 2000, pp. 551-560
Authors:
Kim, DK
Lee, N
Ryu, DH
Kim, YW
Kim, JS
Chang, K
Im, GJ
Choi, WS
Cho, YB
Kim, KH
Colledge, D
Locarnini, S
Citation: Dk. Kim et al., Synthesis and evaluation of 2-amino-9-(3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir, BIO MED CH, 7(8), 1999, pp. 1715-1725
Citation: S. Locarnini et C. Birch, Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients, J HEPATOL, 30(3), 1999, pp. 536-550
Citation: Jy. Lee et al., Pathogenic effects of antiviral therapy in chronic hepatitis B virus infection, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 285-302